This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
Status:
Completed
Trial end date:
2021-05-26
Target enrollment:
Participant gender:
Summary
The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and
Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety
Secondary objectives of Part 1 are to evaluate the efficacy and safety of BI 730357 through
24 weeks of treatment